Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced by applying an inert reference antibody that does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.

Abstract: A signal associated with a motor is obtained where the motor is included in a aircraft that has flight capabilities. A motor wear metric that represents an amount of wear experienced by the motor is determined based at least in part on the signal. It is determined, at a flight computer that is included in the aircraft, whether to restrict the flight capabilities of the aircraft based at least in part on the motor wear metric. The flight capabilities of the aircraft are restricted in the event it is so determined.

Abstract: A method includes acquiring data indicating a plurality of sensor detection values arranged in order along a specific variable axis, detecting, in the data, a plurality of change points that are data points at which the sensor detection value on the specific variable axis changes by a predetermined value or more, and calculating, for a target change point that is one change point among the plurality of change points, an index value representing a degree of abnormality using the target change point and a reference change point that is another change point.

Abstract: Personal dependency related to fault tree construction is reduced, and the reliability of an operating machine is improved by improving the accuracy of a fault diagnosis.

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

Abstract: A time series data processing apparatus according to the present invention includes an extracting unit configured to extract, from normal period time series data that is time series data of a period during which a measurement target is determined to be in a normal state of time series data including a plurality of parameters based on data measured from the measurement target, a combination of the plurality of parameters in which a value of another parameter with respect to a value of a predetermined parameter is maximum among combinations of the plurality of parameters, as a normal period maximum value.

Abstract: An abnormality determination method includes: a first distance calculation step of calculating, based on measurement data of an object, a first Mahalanobis distance in a first unit space corresponding to a normal mode of the object; a second distance calculation step of calculating, based on the measurement data, an (i+1)-th Mahalanobis distance in an (i+1)-th unit space corresponding to an i-th abnormal mode of the object for each integer i greater than or equal to 1 and less than or equal to N, N being an integer greater than or equal to 2; and an abnormality determination step of determining, based on the second to (N+1)-th Mahalanobis distances, one of the first to N-th abnormal modes where the object is when the first Mahalanobis distance exceeds a threshold value.

Abstract: Provided is a measurement data recording apparatus including: an acquisition portion configured to acquire time-series measurement data obtained by measuring a state of a target; a recording portion configured to record the acquired measurement data; a measurement data transmission portion configured to transmit the measurement data recorded in the recording portion to a generation apparatus configured to generate a determination model for determining a quality of the state of the target; a model reception portion configured to receive the determination model generated by the generation apparatus; and a determination portion configured to determine the quality of the state of the target from newly acquired measurement data using the received determination model.

Abstract: A meter electronics (20) for determining a decay characteristic of a meter assembly (10) of a flow meter (5) is provided. The meter electronics (20) includes an interface (201) for receiving a vibrational response from a meter assembly (10), the vibrational response comprising a response to an excitation of the meter assembly (10) at a substantially resonant frequency, and a processing system (203) in communication with the interface (201). The processing system (203) is configured to receive the vibrational response from the interface (201), determine a response voltage (V) of the vibrational response, determine a decay characteristic (?) of the meter assembly (10) based on the response voltage (V), and compensate the decay characteristic (?) by using a previously determined decay characteristic-to-response voltage relationship.

Abstract: Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.

Abstract: The present method predicts and separates dispersive surface waves from seismic data using dispersion estimation and is completely data-driven and computer automated and no human intervention is needed. The method is capable of predicting and suppressing surface waves from recorded seismic data without damaging the reflections. Nonlinear signal comparison (NLSC) is used to obtain a high resolution and accurate dispersion. Based on the dispersion, surface waves are predicted from the field recorded seismic data. The predicted surface waves are then subtracted from the original data.

Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.

Abstract: An evaluation method and an evaluation device for evaluating a health state of well site equipment, and a storage medium are provided. The evaluation method for evaluating the health state of the well site equipment includes: obtaining operating parameters of a component to be tested of equipment to be tested in at least one dimension, the at least one dimension including an operating data dimension, an environmental data dimension, and a maintenance data dimension; obtaining evaluation values of a health state of the component to be tested in various dimensions based on the operating parameters of the various dimensions; obtaining a comprehensive evaluation value of the health state of the component to be tested based on the evaluation values of the health state of the component to be tested in the various dimensions.

Abstract: According to one embodiment, an information processing apparatus includes: a processor configured to select a first case based on subject data including at least one feature, and acquire a first prediction value that is a value of an objective variable included in the first case; a first estimator configured to estimate frequency data indicating frequencies of observation values of the objective variable, based on a history of observation values of the objective variable; a second estimator configured to estimate first frequency data indicating frequencies of first prediction values, based on a history of first prediction values acquired before the first prediction value is acquired; and a corrector configured to correct the first prediction value acquired by the processor, based on the frequency data and the first frequency data.

Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

Abstract: The present invention provides a protein complex comprising heterodimerizing regions HRI and HRII, each comprised of antiparallel ?-strands and intervening regions wherein HRI and HRII are each interspersed fusion proteins of two human constant regions of an immunoglobulin or immunoglobulin-like proteins. The present invention also provides nucleic acid molecules comprising a sequence encoding said protein complexes and vectors comprising the nucleic acid. The present invention also provides the protein complex, the nucleic acid and the vector for use as a medicament. The present invention further provides a method of determining the amino acid sequence of HRI and/or of the amino acid sequence of HRII. The present invention also provides a method of producing amino acid chains of HRI and/or amino acid chains of HRII. The present invention further provides the protein complex for use in the N prophylaxis, treatment or diagnosis of a disorder or a disease.

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Abstract: The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.

Abstract: Polypeptides are provided that bind CD123 on a target cell and the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of CD123 associated cancers or inflammatory conditions.

Abstract: Various embodiments described herein relate to an anomaly detection framework adaptable to different asset types. In this regard, a data stream associated with a first asset is received. The data stream is then processed to generate output data by encoding the data stream based on historical data associated with the first asset, the historical data comprising clustered data representative of fault states and one or more non-fault states. Furthermore, in accordance with a determination that the generated output data is indicative of a potential fault of the first asset, fault data indicative of the potential fault is generated and caused to be transmitted to an administrative device for display.